UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies

Frontiers in oncology, 2020-01, Vol.9, p.1380-1380

2020

Volltextzugriff (PDF)

Improving attribution of adverse events in oncology clinical trials

Cancer treatment reviews, 2019-06, Vol.76, p.33-40

2019

Volltextzugriff (PDF)

Blazing the pharmacologic audit trail: Pharmacodynamic biomarkers in early drug development

Clinical cancer research, 2010-10, Vol.16 (19_Supplement), p.PL6-1-PL6-1

Takimoto, Chris H.

2010

Volltextzugriff (PDF)

New Antifolates: Pharmacology and Clinical Applications

The oncologist (Dayton, Ohio), 1996-02, Vol.1 (1-2), p.68-81

Takimoto, Chris H.

1996

Volltextzugriff (PDF)

Translational Study of Cell Surface Proteins in Non-Hodgkin Lymphoma Patients Treated with the First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Rituximab

Blood, 2019-11, Vol.134 (Supplement_1), p.5229-5229

2019

Volltextzugriff (PDF)

Novel Designs of Early Phase Trials for Cancer Therapeutics

Shivaani Kummar, Chris Takimoto

1, 2018

Volltextzugriff (PDF)

RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9

Blood, 2018-11, Vol.132 (Supplement 1), p.2327-2327

2018

Volltextzugriff (PDF)

Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia

Blood, 2018-11, Vol.132 (Supplement 1), p.2729-2729

2018

Volltextzugriff (PDF)

An All Antibody Approach for Conditioning Bone Marrow for Hematopoietic Stem Cell Transplantation with Anti-cKIT and Anti-CD47 in Non-Human Primates

Blood, 2019-11, Vol.134 (Supplement_1), p.4428-4428

2019

Volltextzugriff (PDF)

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

Blood, 2019-11, Vol.134 (Supplement_1), p.569-569

2019

Volltextzugriff (PDF)

Abstract 3365: Population pharmacokinetics of oxaliplatin: An analysis across human development in infants, children and adults

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3365-3365

2013

Volltextzugriff (PDF)

Can tamoxifen therapy be optimized for patients with breast cancer on the basis of CYP2D6 activity assessments?

Nature clinical practice. Oncology, 2007-03, Vol.4 (3), p.152-153

Takimoto, Chris H

2007

Volltextzugriff (PDF)

Maximum tolerated dose: clinical endpoint for a bygone era?: Toxicities

Targeted oncology, 2009, Vol.4 (2), p.143-147

TAKIMOTO, Chris H

2009

Volltextzugriff (PDF)

Can docetaxel dosing be individualized based on cytochrome p450 activity?

Nature clinical practice. Oncology, 2005-09, Vol.2 (9), p.446-447

Takimoto, Chris H

2005

Volltextzugriff (PDF)

Abstract A37: Development of biologics targeting soluble ligands: Novel biomarker and PK-PD analyzes examining free and total ligand profile following treatment with carlumab (anti-CCL2 mAb)

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.A37-A37

2011

Volltextzugriff (PDF)

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase 1 NCI Organ Dysfunction Working Group Study NCI-6432

Clinical cancer research, 2012-03, Vol.18 (10)

2012

Volltextzugriff (PDF)

Foreword

Current problems in cancer, 2006-01, Vol.30 (1), p.6

Takimoto, Chris H.

2006

Volltextzugriff (PDF)

Pharmacokinetics and Safety of Bortezomib In Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Results of the Phase 1 National Cancer Institute Organ Dysfunction Working Group Study NCI 6432

Blood, 2010-11, Vol.116 (21), p.3975-3975

2010

Volltextzugriff (PDF)

Foreword

Current problems in cancer, 2005-01, Vol.29 (1), p.7

Takimoto, Chris H.

2005

Volltextzugriff (PDF)

Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies

Cancer chemotherapy and pharmacology, 2010, Vol.65 (1), p.167-175

2010

Volltextzugriff (PDF)

Commentary on “Thymidylate Synthase Pharmacogenetics in Colorectal Cancer”

Clinical colorectal cancer, 2001-11, Vol.1 (3), p.181-181

Takimoto, Chris H.

2001

Volltextzugriff (PDF)

Heat shock protein and proteasome targeting agents: Targeted Therapies

Hematology/oncology clinics of North America, 2002, Vol.16 (5)

2002

Volltextzugriff (PDF)

Chapter 30 - Nonclinical drug development

Atkinson's Principles of Clinical Pharmacology, 2022, p.573-588

Fourth Edition, 2022

Volltextzugriff (PDF)

Thymidylate Synthase Pharmacogenetics in Colorectal Cancer

Clinical colorectal cancer, 2001-11, Vol.1 (3), p.181-181

Takimoto, Chris H

2001

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(35)

Publikationsform

Sprache

Englisch
(44)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies

Improving attribution of adverse events in oncology clinical trials

Blazing the pharmacologic audit trail: Pharmacodynamic biomarkers in early drug development

Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies

New Antifolates: Pharmacology and Clinical Applications

Translational Study of Cell Surface Proteins in Non-Hodgkin Lymphoma Patients Treated with the First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Rituximab

Novel Designs of Early Phase Trials for Cancer Therapeutics

RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9

Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia

An All Antibody Approach for Conditioning Bone Marrow for Hematopoietic Stem Cell Transplantation with Anti-cKIT and Anti-CD47 in Non-Human Primates

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

Abstract 3365: Population pharmacokinetics of oxaliplatin: An analysis across human development in infants, children and adults

Can tamoxifen therapy be optimized for patients with breast cancer on the basis of CYP2D6 activity assessments?

Maximum tolerated dose: clinical endpoint for a bygone era?: Toxicities

Can docetaxel dosing be individualized based on cytochrome p450 activity?

Abstract A37: Development of biologics targeting soluble ligands: Novel biomarker and PK-PD analyzes examining free and total ligand profile following treatment with carlumab (anti-CCL2 mAb)

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase 1 NCI Organ Dysfunction Working Group Study NCI-6432

Foreword

Pharmacokinetics and Safety of Bortezomib In Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Results of the Phase 1 National Cancer Institute Organ Dysfunction Working Group Study NCI 6432

Foreword

Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies

Commentary on “Thymidylate Synthase Pharmacogenetics in Colorectal Cancer”

Heat shock protein and proteasome targeting agents: Targeted Therapies

Chapter 30 - Nonclinical drug development

Thymidylate Synthase Pharmacogenetics in Colorectal Cancer

Aktive Filter

Suchergebnisse filtern